View this email in your browser ([link removed])
[link removed] June 11, 2025


** New Report: Getting PrEP Rollout Right This Time
------------------------------------------------------------

Dear Advocate,

AVAC is delighted to release its new report, Getting PrEP Rollout Right This Time: Lessons from the Field, ([link removed]) that examines key insights from the rollout of oral PrEP and early introduction of injectable cabotegravir ([link removed]) (CAB) and the dapivirine vaginal ring ([link removed]) (DVR) to inform a faster, smarter and more equitable introduction of future HIV prevention tools, including long-acting injectable PrEP, such as lenacapavir ([link removed]) .
[link removed]

AVAC conducted in-depth interviews with policymakers, program implementers, and advocates in seven countries (Brazil, Kenya, Nigeria, South Africa, Vietnam, Zambia, and Zimbabwe) to understand how policy, procurement, service delivery, and community engagement have shaped the uptake of oral PrEP and the introduction on DVR and CAB. The findings offer critical insights into what must change, what must be sustained, and what must be built to ensure new HIV prevention options are rolled out with speed, scale and equity.

This analysis comes at a pivotal moment as the US Administration is actively working to dismantle HIV research ([link removed]) and demolish the architecture of global health. The entire HIV response from basic research and clinical development to policy, programs, and global access to life-saving treatment and prevention is now under attack. All this as the field reaches a moment of historic promise ([link removed]) in HIV prevention, with initial regulatory approval of LEN for PrEP ([link removed]) from the US Food and Drug Administration expected by next Thursday, June 19. This report lays out what’s needed at this critical time to get HIV prevention into the hands of those that need it most.

For those attending IAS 2025 in Kigali, Rwanda, next month, please be sure to join us at a special session on Monday, July 14 Re-imagining prevention: Ensuring sustainable PrEP access in an evolving funding context ([link removed]) . And for those not in Kigali, we’ll be hosting a follow-up webinar to unpack the findings – and the next steps – soon.

At a time of extraordinary promise, and great political uncertainty, we hope you will join other advocates, implementers, and policymakers during this webinar and together chart the way forward.
Webinar
JOIN US TODAY, Wednesday, June 11 @ 11.00am ET


** The Scientific Journey of Lenacapavir: From basic science to clinical development to impact
------------------------------------------------------------

Learn how sustained US support from NIH discovery science to South Africa’s clinical research infrastructure made the development of LEN for PrEP possible.

Speakers include:
* Wes Sundquist (University of Utah), on the early-stage science behind capsid inhibitors.

* Linda-Gail Bekker (Desmond Tutu HIV Foundation), on the PURPOSE 1 trial in South Africa, where not a single HIV infection occurred.

Register Now ([link removed])

In solidarity,

AVAC
Follow us @hivpxresearch ([link removed])
[link removed] [link removed] [link removed]
Share this issue ([link removed])
AVAC Global Advocacy for HIV Prevention
+1 212 796 6423 [email protected] (mailto:[email protected]) www.avac.org ([link removed])
You're receiving this because you signed up for our newsletter. Not interested any longer?
Manage email preferences ([link removed]) | Unsubscribe ([link removed])